JP5288365B2 - 統合失調症の検査および治療 - Google Patents

統合失調症の検査および治療 Download PDF

Info

Publication number
JP5288365B2
JP5288365B2 JP2007214047A JP2007214047A JP5288365B2 JP 5288365 B2 JP5288365 B2 JP 5288365B2 JP 2007214047 A JP2007214047 A JP 2007214047A JP 2007214047 A JP2007214047 A JP 2007214047A JP 5288365 B2 JP5288365 B2 JP 5288365B2
Authority
JP
Japan
Prior art keywords
phenyl
methyl
dihydro
group
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007214047A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009039088A5 (enExample
JP2009039088A (ja
Inventor
昌成 糸川
敏男 宮田
誠 新井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tokyo Metropolitan Institute of Medical Science
Medical and Biological Laboratories Co Ltd
RenaScience Co Ltd
Tokai University Educational System
Original Assignee
Tokyo Metropolitan Institute of Medical Science
Medical and Biological Laboratories Co Ltd
RenaScience Co Ltd
Tokai University Educational System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2007214047A priority Critical patent/JP5288365B2/ja
Application filed by Tokyo Metropolitan Institute of Medical Science, Medical and Biological Laboratories Co Ltd, RenaScience Co Ltd, Tokai University Educational System filed Critical Tokyo Metropolitan Institute of Medical Science
Priority to PL08792016T priority patent/PL2189537T3/pl
Priority to DK08792016.1T priority patent/DK2189537T3/da
Priority to EP20130003496 priority patent/EP2662453A3/en
Priority to EP08792016.1A priority patent/EP2189537B1/en
Priority to HRP20140993AT priority patent/HRP20140993T1/hr
Priority to SI200831305T priority patent/SI2189537T1/sl
Priority to US12/674,018 priority patent/US8809329B2/en
Priority to PCT/JP2008/063803 priority patent/WO2009025159A1/ja
Priority to PT87920161T priority patent/PT2189537E/pt
Priority to ES08792016.1T priority patent/ES2515168T3/es
Publication of JP2009039088A publication Critical patent/JP2009039088A/ja
Publication of JP2009039088A5 publication Critical patent/JP2009039088A5/ja
Application granted granted Critical
Publication of JP5288365B2 publication Critical patent/JP5288365B2/ja
Priority to US14/325,808 priority patent/US20140335517A1/en
Priority to CY20141100824T priority patent/CY1115640T1/el
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2007214047A 2007-07-17 2007-08-20 統合失調症の検査および治療 Expired - Fee Related JP5288365B2 (ja)

Priority Applications (13)

Application Number Priority Date Filing Date Title
JP2007214047A JP5288365B2 (ja) 2007-07-17 2007-08-20 統合失調症の検査および治療
ES08792016.1T ES2515168T3 (es) 2007-08-20 2008-07-31 Detección y tratamiento de la esquizofrenia
EP20130003496 EP2662453A3 (en) 2007-08-20 2008-07-31 Detection and treatment of schizophrenia
EP08792016.1A EP2189537B1 (en) 2007-08-20 2008-07-31 Detection and treatment of schizophrenia
HRP20140993AT HRP20140993T1 (hr) 2007-08-20 2008-07-31 Otkrivanje i lijeäśenje shizofrenije
SI200831305T SI2189537T1 (sl) 2007-08-20 2008-07-31 Detekcija in zdravljenje shizofrenije
US12/674,018 US8809329B2 (en) 2007-08-20 2008-07-31 Detection and treatment of schizophrenia
PCT/JP2008/063803 WO2009025159A1 (ja) 2007-08-20 2008-07-31 統合失調症の検査および治療
PL08792016T PL2189537T3 (pl) 2007-08-20 2008-07-31 Wykrywanie i leczenie schizofrenii
DK08792016.1T DK2189537T3 (da) 2007-08-20 2008-07-31 Detektion og behandling af skizofreni
PT87920161T PT2189537E (pt) 2007-08-20 2008-07-31 Detecção e tratamento da esquizofrenia
US14/325,808 US20140335517A1 (en) 2007-08-20 2014-07-08 Detection and treatment of schizophrenia
CY20141100824T CY1115640T1 (el) 2007-08-20 2014-10-10 Διαγνωση και αγωγη εναντι της σχιζοφρενειας

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007186371 2007-07-17
JP2007186371 2007-07-17
JP2007214047A JP5288365B2 (ja) 2007-07-17 2007-08-20 統合失調症の検査および治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013108428A Division JP5738346B2 (ja) 2007-07-17 2013-05-22 統合失調症の検査

Publications (3)

Publication Number Publication Date
JP2009039088A JP2009039088A (ja) 2009-02-26
JP2009039088A5 JP2009039088A5 (enExample) 2010-09-30
JP5288365B2 true JP5288365B2 (ja) 2013-09-11

Family

ID=40378067

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007214047A Expired - Fee Related JP5288365B2 (ja) 2007-07-17 2007-08-20 統合失調症の検査および治療

Country Status (11)

Country Link
US (2) US8809329B2 (enExample)
EP (2) EP2189537B1 (enExample)
JP (1) JP5288365B2 (enExample)
CY (1) CY1115640T1 (enExample)
DK (1) DK2189537T3 (enExample)
ES (1) ES2515168T3 (enExample)
HR (1) HRP20140993T1 (enExample)
PL (1) PL2189537T3 (enExample)
PT (1) PT2189537E (enExample)
SI (1) SI2189537T1 (enExample)
WO (1) WO2009025159A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2441764B1 (en) 2009-06-12 2017-03-22 Bioneer Corporation Use of 4-methylenyl-5-oxo-1,5-dihydro-4H-pyrazol, 5-methylenyl-5H-cyclopenta[b]pyridine and pyrimidine-2,4,6(1H,3H,5H)-trione derivatives and related compounds for RNAase inhibition in RNA sample storage containers
WO2011142460A1 (ja) * 2010-05-14 2011-11-17 財団法人東京都医学総合研究所 統合失調症の検出方法
CN102993191B (zh) * 2012-12-18 2015-05-27 苏州大学 一种含有吖内酯与吡唑啉酮的杂环手性化合物及其衍生物、合成方法及用途
EP3187185A4 (en) 2014-08-29 2018-04-11 Project PM Co., Ltd. Pharmaceutical composition formed by combining pyridoxamine compound and thiamine compound
KR101796391B1 (ko) * 2015-07-24 2017-11-09 동국대학교 산학협력단 Blt 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 조성물
JP6105111B1 (ja) 2016-03-02 2017-03-29 国立大学法人東北大学 自閉スペクトラム症改善用組成物
JP6924964B2 (ja) * 2017-07-07 2021-08-25 パナソニックＩｐマネジメント株式会社 情報提供方法、情報処理システム、情報端末、及び情報処理方法
CN109982639A (zh) * 2017-07-07 2019-07-05 松下知识产权经营株式会社 信息提供方法、信息处理系统、信息终端及信息处理方法
KR20200024743A (ko) * 2017-07-07 2020-03-09 파나소닉 아이피 매니지먼트 가부시키가이샤 정보 제공 방법, 정보 처리 시스템, 정보 단말, 및 정보 처리 방법
JP7270600B2 (ja) 2018-02-27 2023-05-10 キッコーマン株式会社 新規酵素及びそれを用いたペントシジンの測定方法
US20220396822A1 (en) * 2019-08-27 2022-12-15 Kikkoman Corporation Method for Measuring Pentosidine and Measurement Kit

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52102431A (en) 1976-02-25 1977-08-27 Kyowa Hakko Kogyo Co Ltd Remedies for mental disorder
JP3507884B2 (ja) 2000-03-07 2004-03-15 新潟大学長 遺伝子発現を指標とする統合失調症の客観的診断法
CA2436522A1 (en) 2001-01-31 2002-08-08 Katia Vancompernolle Phosphorylated glyoxalase i and its use
JP2003038198A (ja) 2001-07-27 2003-02-12 Univ Niigata 精神分裂病により発現量が変化する遺伝子を規定する核酸を解析する方法
NL1019368C2 (nl) * 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
JP2003212795A (ja) 2002-01-15 2003-07-30 Japan Science & Technology Corp 精神分裂病の診断薬
WO2004005935A1 (ja) 2002-07-04 2004-01-15 Mitsubishi Pharma Corporation 統合失調症の検査、診断方法
JP2004251865A (ja) 2003-02-19 2004-09-09 Takashi Muramatsu 統合失調症およびアルツハイマー病の検査薬
JP4143498B2 (ja) 2003-07-31 2008-09-03 独立行政法人科学技術振興機構 統合失調症の判定方法
CN1886386A (zh) 2003-09-30 2006-12-27 三共株式会社 具有四唑环或噻唑烷二酮环的亚苯基衍生物
US20050249823A1 (en) 2003-11-04 2005-11-10 Murphy Tanya K Methods for the prevention or amelioration of neuropsychiatric and related diseases
JP4837992B2 (ja) 2003-12-05 2011-12-14 学校法人東海大学 蛋白修飾物生成抑制剤
JP2005278490A (ja) 2004-03-29 2005-10-13 Japan Science & Technology Agency 統合失調症に関与する生物学的マーカーの判定方法およびその利用
JP5079503B2 (ja) 2005-06-07 2012-11-21 株式会社インバイオテックス ラジカルスカベンジャー及び活性酸素消去剤
TW200720261A (en) 2005-08-31 2007-06-01 Sankyo Co Phenylene derivatives

Also Published As

Publication number Publication date
PL2189537T3 (pl) 2015-01-30
EP2189537B1 (en) 2014-10-08
DK2189537T3 (da) 2014-10-27
SI2189537T1 (sl) 2014-11-28
EP2189537A4 (en) 2010-08-11
HRP20140993T1 (hr) 2014-12-19
US20110028470A1 (en) 2011-02-03
JP2009039088A (ja) 2009-02-26
EP2189537A1 (en) 2010-05-26
US20120065198A2 (en) 2012-03-15
EP2662453A3 (en) 2014-02-26
EP2662453A2 (en) 2013-11-13
WO2009025159A1 (ja) 2009-02-26
PT2189537E (pt) 2014-10-30
US20140335517A1 (en) 2014-11-13
US8809329B2 (en) 2014-08-19
CY1115640T1 (el) 2017-01-04
ES2515168T3 (es) 2014-10-29

Similar Documents

Publication Publication Date Title
US8809329B2 (en) Detection and treatment of schizophrenia
US12012634B2 (en) Methods for diagnosing, prognosing, and treating parkinson's disease or parkinsonism
US10765739B2 (en) Use of MIF and MIF pathway agonists
CN102483415B (zh) 基于odc1基因型的癌诊断与治疗
TW201142293A (en) Predictive markers useful in the treatment of fragile X syndrome (FXS)
US20080249103A1 (en) Sirtuin polymorphisms and methods of use thereof
WO2011046991A2 (en) Certain substituted ureas as modulators of kinase activity
JP5738346B2 (ja) 統合失調症の検査
Thiel et al. A rare PRSS1 p. S127C mutation is associated with chronic pancreatitis and causes misfolding-induced ER-stress
JP2003504007A (ja) 神経変性性疾患における脳の特異的な領域での異なる遺伝子発現
US9567637B2 (en) Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease
US20250241902A1 (en) Methods, compositions and systems for evaluation of visual function
WO2010114686A2 (en) Modulation of abcg2-mediated urate transport to treat hyperuricemia and gout
JP5840124B2 (ja) 統合失調症の検出方法
WO2007129598A1 (ja) グルタチオン増加物質のスクリーニング方法
US20240248099A1 (en) Biomarkers for age-related macular degeneration
Chistiakov et al. Replication of association between polymorphisms of the pancreatic ATP-sensitive potassium channel and susceptibility to type 2 diabetes in two Russian urban populations
Ruiz-Pesini et al. Molecular Insights into Mitochondrial Protein Translocation and Human Disease. Genes 2021, 12, 1031
US20170037471A1 (en) Methods for diagnosing & treating copper-dependent diseases
WO2015100300A2 (en) Methods for diagnosing and treating copper-dependent diseases

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090121

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130307

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130409

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130430

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130528

R150 Certificate of patent or registration of utility model

Ref document number: 5288365

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees